title: Agonism and inverse agonism at dopamine D2-like receptors.
abstract: 1. The processes that follow the binding of ligands to receptors are critical for their physiological functions. In the present paper I intend to review our own work and the work of other laboratories attempting to understand these processes for the dopamine D2-like receptors (D2, D3, D4) and how they contribute to the mechanisms of drug action. It is thought that the key event in agonist action for these receptors is the stabilization, by the agonist, of the agonist-receptor-G-protein ternary complex. The majority of the work I shall describe has been performed using recombinant receptors expressed in cell lines and the mechanisms of receptor action have been probed using ligand binding (competition vs [3H]-spiperone), the stimulation of [35S]-GTP gamma S binding and inhibition of adenylyl cyclase. 2. Measures of the ability of agonists to stabilize the agonist-receptor-G-protein ternary complex may be obtained in ligand-binding studies using the ratio of dissociation constants for the higher and lower affinity states (KI/KH ratio). The stimulation of [35S]-GTP gamma S binding provides a very convenient assay for agonist action and allows the determination of agonist potency and maximal response. Estimates of these quantities may also be obtained from the inhibition of adenylyl cyclase. For a range of agonists at the D2 receptor, there is a tendency for high values of KI/KH to predict high maximal activity and vice versa, but there is no general correlation. This suggests that the simple scheme of agonist action depending on the stabilization of the ternary complex is an over-simplification and further efficacy determining steps need to be included. For a number of receptors, including the D2 and D3 receptors, it has now been shown that there is activity in the absence of agonist (so-called constitutive activity). This agonist-independent activity can be inhibited by compounds previously considered to be antagonists (e.g. the antipsychotic drugs). Therefore, these compounds are inverse agonists rather than antagonists. The mechanism of this inverse agonist effect is unclear and we are examining this using a variety of biochemical approaches, including the use of constitutively active mutants. 3. The mechanisms of agonism and inverse agonism may be probed using biochemical assays and these studies are of great relevance to the understanding of drug action.
authors.affiliation: School of Animal and Microbial Sciences, University of Reading, United Kingdom. P.G.Strange@reading.ac.uk
authors.forename: P G
authors.initials: PG
authors.lastname: Strange
mesh_terms: D018491:Dopamine Agonists / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology*; D006801:Humans; D008024:Ligands; D017448:Receptors, Dopamine D2 / Q000502:physiology*
chemical_list: D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D008024:Ligands; D017448:Receptors, Dopamine D2